SCHEMBL11926284

SCHEMBL11926284

Cc1[nH]c2ccc(NC(=O)c3cc(NCC(=O)N4CCC(O)CC4)nc(N4CCOCC4)n3)cc2c1C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ PDE7A Q13946 1/20 0.37
▸ TERT O14746 1/20 0.37
▸ RAF1 P04049 7/20 0.37
▸ BRAF P15056 7/20 0.37
▸ MCHR1 Q99705 1/20 0.37
▸ TLR9 Q9NR96 2/20 0.36
▸ TLR8 Q9NR97 2/20 0.36
▸ TLR7 Q9NYK1 2/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11926274 0.94 ALDH1A1 (0.43) KDM4EALDH1A1L3MBTL1MEN1NPC1
SCHEMBL11926290 0.92 ALDH1A1 (0.43) KDM4EALDH1A1L3MBTL1MEN1NPC1
SCHEMBL11926281 0.92 PIK3CA (0.42) KDM4EALDH1A1L3MBTL1MEN1NPC1
SCHEMBL11926291 0.92 ALDH1A1 (0.44) KDM4EALDH1A1L3MBTL1MEN1NPC1
SCHEMBL11926286 0.91 KDM4E (0.41) KDM4EALDH1A1L3MBTL1NPC1TERT
SCHEMBL11926282 0.91 ALDH1A1 (0.41) KDM4EALDH1A1L3MBTL1MEN1NPC1
SCHEMBL3116305 0.88 PIN1 (0.44) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL11926287 0.87 ALDH1A1 (0.42) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3103694 0.86 PIK3CA (0.42) KDM4EALDH1A1L3MBTL1MEN1NPC1
SCHEMBL5498253 0.85 AKT1 (0.44) KDM4EALDH1A1L3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236795-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2012-08-07 — — US disclosed
US-8236795-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2012-08-07 — — US disclosed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 — — US disclosed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 — — US disclosed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS IL2, IL4, IFNG KDM4E 3666/4885ALDH1A1 1381/4885L3MBTL1 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback